With evolving technologies and methodologies, human ADME studies continue to be a cornerstone of drug development.
- What innovative approaches (e.g., microsampling, isotopic labeling, in silico models) have you seen making an impact?
- How do we address challenges in balancing precision with efficiency in ADME profiling?
Look forward to know about your experiences and insights.
------------------------------
Pankajini Mallick Ph.D.
Sr. Principal Scientist, Preclinical Pharmacokinetics | Modeling and Simulation
San Diego CA
Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------